|
| Scientists compared the allogeneic hematopoietic cell transplantation (allo-HCT) outcomes of cord blood transplantation versus single-allele-mismatched mismatched unrelated donor allo-HCT with post-transplant cyclophosphamide in acute myeloid leukemia.
[Journal of Hematology & Oncology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| A cord blood product was analyzed by three methods for cell viability, two methods for assessment of cell morphology and cell type, multicolor flow cytometry to identify stem cells, and enzyme-linked immunosorbent assay.
[The American Journal of Sports Medicine] |
|
|
|
| Researchers investigated the effects of extracellular vehicles secreted by human umbilical cord mesenchymal stem cells on angiogenesis under high glucose conditions in vivo and in vitro and to explore the underlying mechanisms.
[Stem Cell Reviews and Reports] |
|
|
|
|
| The authors evaluated the effects of two consecutive days of intratracheal administration of surfactant and human umbilical cord-MSC on hyperoxia-induced lung injury.
[Stem Cell Research & Therapy] |
|
|
|
| Scientists tested the hypothesis that combined therapy with human umbilical cord‐derived MSCs and hyperbaric oxygen was superior to either one on preserving neurological function and reducing brain hemorrhagic volume in rat after acute intracerebral hemorrhage induced by intracranial injection of collagenase.
[Journal of Cellular and Molecular Medicine] |
|
|
|
|
| The authors compile and discuss study design data from ongoing clinical trials to address the key questions of ‘which’ tissue source, donor profile, isolation technique, culture conditions, long-term culture and cryopreservation for MSCs.
[Cytotherapy] |
|
|
|
| Investigators explore the several mechanisms through which MSCs impact on the supportive activity of the bone marrow niche and regulate hematopoietic stem and progenitor cell homeostasis.
[Frontiers in Cell and Developmental Biology] |
|
|
|
|
| Orgenesis, Inc. announced it has been granted Investigational Device Exemption (IDE) approval by the FDA to conduct a first-in-human feasibility study of the Tissue Genesis Icellator2® to treat Acute Respiratory Distress Syndrome (ARDS) resulting from COVID-19 infection.
[Orgenesis, Inc. (GlobeNewswire, Inc.)] |
|
|
|
|
| June 9 – 17, 2021
Virtual |
|
|
|
|
|
| | Ncardia- Leiden, The Netherlands |
|
|
|
| | Indiana University School of Medicine – Indianapolis, Indiana, United States |
|
|
|
| | Zhejiang University – Zhejiang, China |
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | Moores Cancer Center – La Jolla, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
